Expert Interview
Discussing Kymera Therapeutics' Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader for potential treatment of IL-4/IL-13-driven allergic diseases
Ticker(s): KYMRInstitution: University of South Florida
- Assistant Professor in the Department of Internal Medicine within the Division of Allergy and Immunology at the University of South Florida Morsani College of Medicine.
- Specializes in the treatment of patients with asthma, chronic urticaria, chronic rhinitis, and other allergic diseases.
- Treats 150 patients with TH-2 driven conditions annually
Describe your background and practice setting
Added By: nick_adminHow many patients with Th2-driven conditions do you currently manage?
Added By: nick_adminCan you describe the standard of care for AD?
Added By: nick_adminWhere could KYMR's KT-621 fit into your treatment algorithm for AD?
Added By: nick_adminRank your excitement for KT-621 on a scale of 1-10
Added By: nick_adminWhat different indications are driven by IL-4/IL-13 pathways?
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
